Antibiotic stewardship is essential to the delivery of precision medicine in healthcare. Selecting the correct antimicrobial therapy for infected patients is crucial for their recovery.

Microbial resistance genes appear due to indiscriminate antibiotic use. Plasmid molecules carrying extra gene copies are quickly acquired by pathogenic bacterial species for their survival by a phenomenon known as transformation.

Resistance to Penicillin related antibiotics such as Vancomycin, Tetracycline, Erythromycin, and others have already emerged. Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus (VRE) and Vancomycin Intermediate Staphylococcus aureus (VISA) are also now becoming a major concern. Several have already become multi-drug resistant (MDR).

Testing for multiple resistant genes such as ampC, blaSHV, ermB, mecA/C, mcr-1, sul1/2, tetM/S, qnrA/B/S and vanA/B, is essential to select the appropriate antibiotics for treating the patient. This allows patients to recover quickly and prevent adverse reactions to antibiotics.

NCF Diagnostics & DNA Technologies created ResistantPath™ alongside each pathogen test. This is a partner test ordered by physicians to evaluate antibiotic resistance of any pathogens present in patients’ specimens.

Our ResistantPath™ panel test screens for seven (7) antibiotic-resistant genes that may be present:

1. mecA, 2. mcr-1, 3. tetM, 4. tetS, 5. vanA, 6. vanB & 7. sul1